Abstract: The claimed invention relates to the field of biologically active compounds and concerns 2-methylsulphanyl-6-nitro-7-oxo-1,2,4-triazolo[5,1-c][1,2,4]triazinide L-arginine dihydrate, which exhibits an antiviral effect and is intended for the treatment and prophylaxis of human and animal viral diseases, primarily West Nile Virus, and can be used in the chemical and pharmaceutical industry, in scientific research laboratories and medical facilities, and also in veterinary science. The claimed invention is directed toward achieving the technical result of creating a novel effective drug of the azoloazine variety which exhibits antiviral activity toward a group of RNA-containing viruses, and reducing the dependence of the active compound on cell metabolism. This technical result is achieved in the creation of the novel drug 2-methylsulphanyl-6-nitro-7-oxo-1,2,4-triazolo[5,1-c][1,2,4]triazinide L-arginine dihydrate, which exhibits an aniviral effect and has the formula (I).

Abstract: The claimed invention relates to the field of biologically active compounds and concerns 2-methylsulphanyl-6-nitro-7-oxo-1,2,4-triazolo[5,1-c][1,2,4]triazinide L-arginine dihydrate, which exhibits an antiviral effect and is intended for the treatment and prophylaxis of human and animal viral diseases, primarily West Nile Virus, and can be used in the chemical and pharmaceutical industry, in scientific research laboratories and medical facilities, and also in veterinary science. The claimed invention is directed toward achieving the technical result of creating a novel effective drug of the azoloazine variety which exhibits antiviral activity toward a group of RNA-containing viruses, and reducing the dependence of the active compound on cell metabolism. This technical result is achieved in the creation of the novel drug 2-methylsulphanyl-6-nitro-7-oxo-1,2,4-triazolo[5,1-c][1,2,4]triazinide L-arginine dihydrate, which exhibits an aniviral effect and has the formula (I).

Abstract: Substitued 6H-1,3,4-thiadiazin-2-amines of the following general formula: wherein Ar is phenyl optionally substituted with one or more chloro, bromo atoms, C1-C4 alkoxy, or C1-C4 alkyl groups; and represents a morpholino, thimomorpholino, piperidino, pyrrolidino, or hexamethylenimino moieties, the pharmaceutically acceptable salts thereof and the use of them anasethetic, cardiovascular and hypometabolic agents and pharmaceutical compositions containing them.

Abstract: Substituted 6-R-1,3,4-thiadiazin-2-amines of the following general formula: ##STR1## wherein Ar is phenyl or phenyl optionally substituted with one or more chloro, bromo atoms, C.sub.1 -C.sub.4 alkoxy or C.sub.1 -C.sub.4 alkyl groups; R.sup.1 and R.sup.2 are each independently hydrogen atom or C.sub.1 -C.sub.4 alkyl moiety; and R.sup.3 and R.sup.4 are independently selected from C.sub.1 -C.sub.4 alkyl groups and pharmaceutically acceptable salts thereof, the use of them as anaesthetics, cardiovascular and hypometabolic agents and pharmaceutical compositions containing them.

Abstract: Substituted 6H-1,3,4-thiadiazin-2-amines of the following general formula: ##STR1## wherein ##STR2## represents a morpholino, thiomorpholino, piperidino, pyrrolidino, or hexamethyienimino moiety, and pharmaceutically acceptable salts thereof which are used as anaesthetics, cardiovascular and hypometabolic agents, and the pharmaceutical compositions containing them.